{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T17:47:03Z","timestamp":1782409623510,"version":"3.54.5"},"reference-count":186,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Vaccines"],"abstract":"<jats:p>Background\/Objectives: Viral hepatitis remains a significant global cause of chronic liver disease, highlighting the importance of effective vaccination strategies. This review assesses recent evidence on vaccine safety and effectiveness. Methods: A comprehensive search of PubMed, Embase, Web of Science, and Scopus identified English-language studies published from January 2000 to September 2025. Eligible studies evaluated vaccination for hepatitis A, B, C, or E, as well as vaccine responses in individuals with chronic liver disease or HIV infection. Of 5254 records screened, 166 studies met the inclusion criteria. Results: Hepatitis A vaccines demonstrated excellent safety, 95\u2013100% short-term seroprotection, and durable immunity for both inactivated and live-attenuated formulations, with population-level reductions in disease incidence. Hepatitis B vaccines showed consistently strong immunogenicity across age groups, with over 90% seroprotection from recombinant and CpG-adjuvanted formulations. Effective prevention of mother-to-child transmission required maternal antiviral therapy, timely birth-dose vaccination, hepatitis B immunoglobulin (HBIG) administration, and post-vaccination serologic testing. Long-term data demonstrated immune persistence for up to 35 years and significant reductions in liver cancer following neonatal HBV vaccination. Limited studies in hepatitis C populations showed impaired responses, partially improved with higher or booster doses. Hepatitis E vaccines showed excellent safety and over 99% seroconversion. In non-viral liver disease and post-transplant populations, vaccine responses were reduced but remained clinically meaningful, especially with adjuvanted or higher-dose HBV vaccines. Among HIV-infected individuals, HAV vaccination was generally effective, while enhanced HBV regimens markedly improved seroprotection. Conclusions: Hepatitis A, B, and E vaccines are safe, immunogenic, and effective, with neonatal hepatitis B vaccination critical for preventing maternal transmission. No licensed HCV vaccine exists, and therapeutic HCV vaccines show limited efficacy. Optimized and targeted vaccination strategies are needed for individuals with chronic liver disease, HIV infection, HCV infection, transplant recipients, and other immunocompromised populations to maximize public health impact.<\/jats:p>","DOI":"10.3390\/vaccines14010049","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:08:00Z","timestamp":1767197280000},"page":"49","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Vaccination Strategies Against Hepatic Diseases: A Scoping Review"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8987-2555","authenticated-orcid":false,"given":"Zahra","family":"Beyzaei","sequence":"first","affiliation":[{"name":"Transplant Research Center, Shiraz University of Medical Sciences, Shiraz 7193711351, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bita","family":"Geramizadeh","sequence":"additional","affiliation":[{"name":"Transplant Research Center, Shiraz University of Medical Sciences, Shiraz 7193711351, Iran"},{"name":"Department of Pathology, Medical School of Shiraz University, Shiraz University of Medical Sciences, Shiraz 7193711351, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Karimzadeh","sequence":"additional","affiliation":[{"name":"Shiraz Medical School Library, Shiraz University of Medical Sciences, Shiraz 7193711114, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3888-0931","authenticated-orcid":false,"given":"Ralf","family":"Weiskirchen","sequence":"additional","affiliation":[{"name":"Institute of Molecular Pathobiochemistry, Experimental Gene Therapy and Clinical Chemistry (IFMPEGKC) RWTH University Hospital Aachen, D-52074 Aachen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1007\/s10238-025-01645-8","article-title":"Hepatitis B virus infection after immunization: How serious it is? An updated review","volume":"25","author":"Marjani","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"229","DOI":"10.21037\/jgo.2017.03.14","article-title":"Viral hepatitis and hepatocellular carcinoma: Etiology and management","volume":"8","author":"Zamor","year":"2017","journal-title":"J. Gastrointest. Oncol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Farbod, Y., Kankouni, H., Moini, M., and Fung, S. (2025). Hepatitis B-Induced Hepatocellular Carcinoma: Understanding Viral Carcinogenesis and Disease Management. J. Clin. Med., 14.","DOI":"10.3390\/jcm14072505"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.3748\/wjg.v28.i14.1405","article-title":"Viral hepatitis: Past, present, and future","volume":"28","author":"Odenwald","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"ref_5","unstructured":"World Health Organization (2021). Global Progress Report on HIV, Viral Hepatitis and Sexually Transmitted Infections, 2021: Accountability for the Global Health Sector Strategies 2016\u20132021: Actions for Impact, World Health Organization."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.coviro.2017.03.011","article-title":"Therapeutic vaccination for chronic hepatitis B","volume":"23","author":"Kosinska","year":"2017","journal-title":"Curr. Opin. Virol."},{"key":"ref_7","first-page":"CD011644","article-title":"Pharmacological interventions for acute hepatitis C infection: An attempted network meta-analysis","volume":"2017","author":"Kalafateli","year":"2017","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s12575-025-00269-2","article-title":"Recent Advances in mRNA-Based Vaccines Against Several Hepatitis Viruses","volume":"27","author":"Albadr","year":"2025","journal-title":"Biol. Proced. Online"},{"key":"ref_9","doi-asserted-by":"crossref","unstructured":"Mironova, M., and Ghany, M.G. (2024). Hepatitis B Vaccine: Four Decades on. Vaccines, 12.","DOI":"10.3390\/vaccines12040439"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"467","DOI":"10.7326\/M18-0850","article-title":"PRISMA Extension for Scoping Reviews (PRISMA-ScR): Checklist and Explanation","volume":"169","author":"Tricco","year":"2018","journal-title":"Ann. Intern. Med."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1016\/j.vaccine.2023.02.073","article-title":"Safety of concomitant administration of inactivated hepatitis A vaccine with other vaccines in children under 16 years old in post-marketing surveillance","volume":"41","author":"Wu","year":"2023","journal-title":"Vaccine"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"2227549","DOI":"10.1080\/21645515.2023.2227549","article-title":"Immunogenicity persistence of hepatitis A vaccines Healive\u00ae and Havrix\u00ae among children:15 years follow-up and long-term prediction","volume":"19","author":"Wang","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1016\/j.vaccine.2023.01.007","article-title":"A randomized phase 3 trial of the immunogenicity and safety of coadministration of a live-attenuated tetravalent dengue vaccine (TAK-003) and an inactivated hepatitis a (HAV) virus vaccine in a dengue non-endemic country","volume":"41","author":"Tricou","year":"2023","journal-title":"Vaccine"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"6215","DOI":"10.1016\/j.vaccine.2023.08.084","article-title":"Immunogenicity and safety of HavisureTM vaccine developed by Human Biologicals Institute in healthy subjects of 12 months to 49 years of age: A phase II\/III, randomized, single blind, non-inferiority study","volume":"41","author":"Susarla","year":"2023","journal-title":"Vaccine"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"7166","DOI":"10.1016\/j.vaccine.2021.10.018","article-title":"A single blind randomized phase 3 study to evaluate safety and immunogenicity of inactivated hepatitis A vaccine (HAPIBEVTM) in 1\u201315 years-old healthy hepatitis A vaccine-na\u00efve children","volume":"39","author":"Thuluva","year":"2021","journal-title":"Vaccine"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1016\/j.vaccine.2021.03.012","article-title":"Safety and immunogenicity of inactivated hepatitis-A vaccine developed by Human Biologicals Institute in two age groups of healthy subjects: A phase I open label study","volume":"39","author":"Susarla","year":"2021","journal-title":"Vaccine"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1002\/jmv.26327","article-title":"Hepatitis A vaccine immunogenicity 25 years after vaccination in Alaska","volume":"93","author":"Ramaswamy","year":"2021","journal-title":"J. Med. Virol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1111\/jvh.13602","article-title":"Long-term persistence of anti-HAV antibody conferred by a single dose of live-attenuated hepatitis A vaccine: Results from 17-year follow-up","volume":"28","author":"Chen","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s13312-021-2285-4","article-title":"Long term Immunogenicity of Single Dose of Live Attenuated Hepatitis A Vaccine in Indian Children\u2014Results of 15-Year Follow-up","volume":"58","author":"Bhave","year":"2021","journal-title":"Indian Pediatr."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1080\/21645515.2020.1715687","article-title":"Immunogenicity persistence in children of hepatitis A vaccines Healive\u00ae and Havrix\u00ae: 11 years follow-up and long-term prediction","volume":"16","author":"Wang","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1080\/21645515.2018.1539600","article-title":"Safety of two doses of an inactivated hepatitis a vaccine given 6 months apart in healthy toddlers, children, and adolescents aged 12 months to 15 years in China: A phase IV study","volume":"15","author":"Shi","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"677","DOI":"10.24953\/turkjped.2019.05.006","article-title":"Impact of the mandatory Hepatitis A immunization program: Before and after the vaccine in Ankara, Central of Turkey","volume":"61","author":"Tezer","year":"2019","journal-title":"Turk. J. Pediatr."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1002\/jmv.25197","article-title":"Hepatitis A vaccine immune response 22 years after vaccination","volume":"90","author":"Mosites","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.vaccine.2017.11.036","article-title":"Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis A vaccine","volume":"36","author":"Chen","year":"2018","journal-title":"Vaccine"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1016\/j.bjid.2018.04.001","article-title":"Initial evaluation of universal immunization with a single dose against hepatitis A virus in Central Brazil","volume":"22","author":"Brito","year":"2018","journal-title":"Braz. J. Infect. Dis."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1080\/21645515.2016.1278329","article-title":"Five-year antibody persistence in children after one dose of inactivated or live attenuated hepatitis A vaccine","volume":"13","author":"Zhang","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1111\/jvh.12676","article-title":"Persistence of antibody to Hepatitis A virus 20 years after receipt of Hepatitis A vaccine in Alaska","volume":"24","author":"Plumb","year":"2017","journal-title":"J. Viral Hepat."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"6412","DOI":"10.1016\/j.vaccine.2017.10.002","article-title":"Immunogenicity of aluminum-adsorbed hepatitis A vaccine (Havrix\u00ae) administered as a third dose after primary doses of Japanese aluminum-free hepatitis A vaccine (Aimmugen\u00ae) for Japanese travelers to endemic countries","volume":"35","author":"Fukushima","year":"2017","journal-title":"Vaccine"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1080\/21645515.2017.1358326","article-title":"Seven-year follow-up of the immune response after one or 2 doses of inactivated hepatitis A vaccine given at 1 year of age in the Mendoza Province of Argentina","volume":"13","author":"Espul","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1080\/21645515.2015.1134069","article-title":"Comparison of immune persistence among inactivated and live attenuated hepatitis a vaccines 2 years after a single dose","volume":"12","author":"Zhang","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2595","DOI":"10.1080\/21645515.2016.1197450","article-title":"Comparison of immunogenicity and persistence between inactivated hepatitis A vaccine Healive\u00ae and Havrix\u00ae among children: A 5-year follow-up study","volume":"12","author":"Yu","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"73","DOI":"10.3346\/jkms.2016.31.1.73","article-title":"Reappraisal of the Immunogenicity and Safety of Three Hepatitis A Vaccines in Adolescents","volume":"31","author":"Yoon","year":"2016","journal-title":"J. Korean Med. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1002\/hep.28375","article-title":"Persistence of seropositivity among persons vaccinated for hepatitis A during infancy by maternal antibody status: 15-year follow-up","volume":"63","author":"Spradling","year":"2016","journal-title":"Hepatology"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"811.e9","DOI":"10.1016\/j.cmi.2016.06.004","article-title":"Comparison of the safety and immunogenicity of live attenuated and inactivated hepatitis A vaccine in healthy Chinese children aged 18 months to 16 years: Results from a randomized, parallel controlled, phase IV study","volume":"22","author":"Ma","year":"2016","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1016\/j.vaccine.2015.07.008","article-title":"Long-term antibody persistence after vaccination with a 2-dose Havrix\u2122 (inactivated hepatitis A vaccine): 20 years of observed data, and long-term model-based predictions","volume":"33","author":"Theeten","year":"2015","journal-title":"Vaccine"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3813","DOI":"10.1016\/j.vaccine.2015.06.099","article-title":"A single dose of inactivated hepatitis A vaccine promotes HAV-specific memory cellular response similar to that induced by a natural infection","volume":"33","author":"Morgado","year":"2015","journal-title":"Vaccine"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"3200","DOI":"10.1016\/j.vaccine.2015.04.100","article-title":"Impact of Hepatitis A vaccination with a two-dose schedule in Panama: Results of epidemiological surveillance and time trend analysis","volume":"33","author":"Estripeaut","year":"2015","journal-title":"Vaccine"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1007\/s13312-015-0697-8","article-title":"Long-term immunogenicity of single dose of live attenuated hepatitis A vaccine in Indian children","volume":"52","author":"Bhave","year":"2015","journal-title":"Indian Pediatr."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.3349\/ymj.2014.55.1.126","article-title":"The immunogenicity of a single dose of hepatitis A virus vaccines (Havrix\u00ae and Epaxal\u00ae) in Korean young adults","volume":"55","author":"Lim","year":"2014","journal-title":"Yonsei Med. J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"2089","DOI":"10.4161\/hv.28631","article-title":"Immunogenicity and safety of a pediatric dose of a virosomal hepatitis A vaccine in healthy children in India","volume":"10","author":"Jain","year":"2014","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2152","DOI":"10.1016\/j.vaccine.2013.02.048","article-title":"Duration of protection against hepatitis A for the current two-dose vaccine compared to a three-dose vaccine schedule in children","volume":"31","author":"Raczniak","year":"2013","journal-title":"Vaccine"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1097\/INF.0b013e318271c4c3","article-title":"An open, prospective, randomized study comparing the immunogenicity and safety of two inactivated hepatitis A pediatric vaccines in toddlers, children and adolescents in China","volume":"32","author":"Li","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1093\/tropej\/49.6.333","article-title":"Immunogenicity and safety of two doses of a paediatric hepatitis A vaccine in thai children: Comparison of three vaccination schedules","volume":"49","author":"Lolekha","year":"2003","journal-title":"J. Trop. Pediatr."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Yang, T.W., Sun, L.N., Zhang, T., Pan, Y.R., Li, J., Li, Y.Y., Han, Z.Y., Sun, W.B., Yao, X.S., and He, X.Y. (2025). Dynamics of HBsAb persistence and associated BCR IgG-H CDR3 repertoire features in ultra-high versus extremely low responders to HBV vaccination. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1587553"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1370\/afm.240184","article-title":"Heplisav-B vs Standard Hepatitis B Vaccine Booster for Health Care Workers","volume":"23","author":"Williams","year":"2025","journal-title":"Ann. Fam. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"3584","DOI":"10.1016\/j.vaccine.2023.05.010","article-title":"The persistence of seroprotective levels of antibodies after vaccination with PreHevbrio, a 3-antigen hepatitis B vaccine","volume":"41","author":"Vesikari","year":"2023","journal-title":"Vaccine"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1111\/trf.17382","article-title":"Development of a recombinant hepatitis B immunoglobulin derived from B cells collected from healthy individuals administered with hepatitis B virus vaccines: A feasibility study","volume":"63","author":"Furuta","year":"2023","journal-title":"Transfusion"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e186","DOI":"10.1017\/S0950268823001747","article-title":"Hepatitis B antibody levels after different doses of hepatitis B vaccination: A retrospective study based on hospitalized children","volume":"151","author":"Chai","year":"2023","journal-title":"Epidemiol. Infect."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1080\/01443615.2021.1946495","article-title":"Application of hepatitis B immunoglobulin in prevention of mother-to-child transmission of chronic hepatitis B in HBsAg- and HBeAg-positive mother","volume":"42","author":"Wang","year":"2022","journal-title":"J. Obstet. Gynaecol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Song, Y., Zhang, X., Liu, M., Zhai, X., Liu, J., Li, Y., Li, L., Xiao, Y., Duan, Z., and Jiang, J. (2022). A booster hepatitis B vaccine for children with maternal HBsAg positivity before 2 years of age could effectively prevent vaccine breakthrough infections. BMC Infect. Dis., 22.","DOI":"10.1186\/s12879-022-07854-w"},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Peng, J., Yao, X., Yuan, C., Liu, X., Xia, R., He, J., Li, R., and Yao, Y. (2022). The Investigation of Hepatitis B Vaccine Immune Responses in Occult Hepatitis B Virus-Infected Patients. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.903685"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"e063482","DOI":"10.1136\/bmjopen-2022-063482","article-title":"Prospective cohort study of prevention of mother to child transmission of hepatitis B infection and 9 months follow-up of hepatitis B-exposed infants at Ile-Ife, Nigeria","volume":"12","author":"Ndububa","year":"2022","journal-title":"BMJ Open"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"5475","DOI":"10.1002\/jmv.28003","article-title":"Pegylated interferon-\u03b1-2b combined with tenofovir disoproxil fumarate, granulocyte-macrophage colony-stimulating factor, and hepatitis B vaccine treatment for na\u00efve HBeAg-positive chronic hepatitis B patients: A prospective, multicenter, randomized controlled study","volume":"94","author":"Lian","year":"2022","journal-title":"J. Med. Virol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"215652","DOI":"10.1016\/j.canlet.2022.215652","article-title":"Long term outcome of prevention of liver cancer by hepatitis B vaccine: Results from an RCT with 37 years","volume":"536","author":"Cao","year":"2022","journal-title":"Cancer Lett."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1002\/hep.32474","article-title":"Protection and antibody levels 35 years after primary series with hepatitis B vaccine and response to a booster dose","volume":"76","author":"Bruce","year":"2022","journal-title":"Hepatology"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"BSR20210182","DOI":"10.1042\/BSR20210182","article-title":"The positive rates of hepatitis B surface antibody in youth after booster vaccination: A 4-year follow-up study with large sample","volume":"41","author":"Zhu","year":"2021","journal-title":"Biosci. Rep."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1111\/jvh.13581","article-title":"Influencing factors and necessity of post-vaccination serologic testing follow-up for HBsAg-positive mothers and their infants: A 5-year prospective study in Zhejiang Province, China (2016\u20132020)","volume":"28","author":"Zhou","year":"2021","journal-title":"J. Viral Hepat."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Zhang, X., Zou, H., Chen, Y., Zhang, H., Tian, R., Meng, J., Zhu, Y., Guo, H., Dai, E., and Zhu, B. (2021). The effects of increased dose of hepatitis B vaccine on mother-to-child transmission and immune response for infants born to mothers with chronic hepatitis B infection: A prospective, multicenter, large-sample cohort study. BMC Med., 19.","DOI":"10.1186\/s12916-021-02025-1"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"e1600","DOI":"10.1016\/S2214-109X(21)00304-1","article-title":"Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: A feasibility study","volume":"9","author":"Thompson","year":"2021","journal-title":"Lancet Glob. Health"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"8676","DOI":"10.1038\/s41598-021-87860-1","article-title":"Hepatitis B virus infection among pregnant mothers and children after the introduction of the universal vaccination program in Central Vietnam","volume":"11","author":"Miyakawa","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"2762","DOI":"10.1080\/21645515.2021.1877079","article-title":"Immune persistence induced by three doses of 60 \u03bcg hepatitis B vaccine in non-responders following standard primary vaccination in Chinese adults","volume":"17","author":"Li","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"5585","DOI":"10.1080\/21645515.2021.1992213","article-title":"The optimal interval for post-vaccination serological test in infants born to mothers with positive hepatitis B surface antigen","volume":"17","author":"Huang","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"6385","DOI":"10.1016\/j.vaccine.2021.09.031","article-title":"A non-inferiority trial comparing two recombinant vaccines (Hepa-B vs. Engerix-B) for hepatitis B among adults in Dhaka, Bangladesh","volume":"39","author":"Chowdhury","year":"2021","journal-title":"Vaccine"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.vaccine.2020.12.050","article-title":"Rapid and high seroprotection rates achieved with a tri-antigenic Hepatitis B vaccine in healthy young adults: Results from a Phase IV study","volume":"39","author":"Atsmon","year":"2021","journal-title":"Vaccine"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1080\/21645515.2019.1666612","article-title":"Long-term persistence of anti-HBs after hepatitis B vaccination among adults: 8-year results","volume":"16","author":"Ren","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/S1473-3099(19)30417-7","article-title":"Serological response to three alternative series of hepatitis B revaccination (Fendrix, Twinrix, and HBVaxPro-40) in healthy non-responders: A multicentre, open-label, randomised, controlled, superiority trial","volume":"20","author":"Raven","year":"2020","journal-title":"Lancet Infect. Dis."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1080\/21645515.2020.1738169","article-title":"Strategies for hepatitis B booster vaccination among children: An 8-year prospective cohort study","volume":"16","author":"Qiu","year":"2020","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1080\/22221751.2020.1808533","article-title":"Reduction of the occurrence of occult HBV infection in infants by increasing the dose of hepatitis B vaccine: A large prospective cohort study","volume":"9","author":"Li","year":"2020","journal-title":"Emerg. Microbes Infect."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.vaccine.2019.10.100","article-title":"Long-term follow-up of a vaccination program for infants born to HBsAg-positive mothers in Stockholm County, Sweden","volume":"38","author":"Insulander","year":"2020","journal-title":"Vaccine"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1016\/j.ajem.2019.158354","article-title":"Hepatitis B screening in an argentine ED: Increasing vaccination in a resource-limited setting","volume":"38","author":"Ford","year":"2020","journal-title":"Am. J. Emerg. Med."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1809223","DOI":"10.1080\/19932820.2020.1809223","article-title":"Hepatitis B birth vaccination, cohort study, Tunisia 2000\u20132017","volume":"15","author":"Dhouib","year":"2020","journal-title":"Libyan J. Med."},{"key":"ref_72","doi-asserted-by":"crossref","unstructured":"Cabezas, C., Trujillo, O., Balbuena, J., Peceros, F.M., Terrazas, M., Su\u00e1rez, M., Marin, L., Apac, J., and Ram\u00edrez-Soto, M.C. (2020). Decrease in the prevalence of hepatitis B and D virus infections in an endemic area in Peru 23 years after the introduction of the first pilot vaccination program against hepatitis B. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0236993"},{"key":"ref_73","doi-asserted-by":"crossref","unstructured":"Zhao, Y.L., Han, B.H., Zhang, X.J., Pan, L.L., Zhou, H.S., Gao, Z., Hao, Z.Y., Wu, Z.W., Ma, T.L., and Wang, F. (2019). Immune persistence 17 to 20\u2009years after primary vaccination with recombination hepatitis B vaccine (CHO) and the effect of booster dose vaccination. BMC Infect. Dis., 19.","DOI":"10.1186\/s12879-019-4134-9"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.vaccine.2018.12.016","article-title":"Immunogenicity and safety of intradermal delivery of hepatitis B booster vaccine using the novel drug delivery device VAX-ID\u2122","volume":"37","author":"Withanage","year":"2019","journal-title":"Vaccine"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/jvh.13125","article-title":"Persistence of HBsAg-specific antibodies and immune memory two to three decades after hepatitis B vaccination in adults","volume":"26","author":"Dionne","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1099\/jmm.0.001086","article-title":"Evaluation of antibody persistence after a four-dose primary hepatitis B vaccination and anamnestic immune response in children under 6 years","volume":"68","author":"Tfifha","year":"2019","journal-title":"J. Med. Microbiol."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1080\/21645515.2018.1554972","article-title":"Comparison of anti-HBs persistence after hepatitis B vaccination on two-dose schedule and three-dose schedule among adults: Results from a 12-year follow up study in China","volume":"15","author":"Lu","year":"2019","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1111\/jpc.14194","article-title":"Comparing monovalent and combination hepatitis B vaccine outcomes in children delivered by mothers with chronic hepatitis B","volume":"55","author":"Lee","year":"2019","journal-title":"J. Paediatr. Child Health"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"9323814","DOI":"10.1155\/2019\/9323814","article-title":"Parents\u2019 Attitude about Hepatitis B Disease and Practice of Hepatitis B Vaccination among Children in Ho Chi Minh City, Vietnam","volume":"2019","author":"Giao","year":"2019","journal-title":"BioMed Res. Int."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.cyto.2017.11.004","article-title":"Biomarkers distinguish HBeAg seroconverted from non-converted individuals in chronic hepatitis B patients treated with a therapeutic vaccine","volume":"106","author":"Zhou","year":"2018","journal-title":"Cytokine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"2207","DOI":"10.1016\/j.vaccine.2018.02.039","article-title":"Antibody response to hepatitis B vaccine is independently associated with hepatitis B breakthrough infection among adults: Results from a three-year follow-up study in China","volume":"36","author":"Zhang","year":"2018","journal-title":"Vaccine"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1080\/21645515.2018.1426419","article-title":"The effects of booster vaccination of hepatitis B vaccine on children 5-15 years after primary immunization: A 5-year follow-up study","volume":"14","author":"Wu","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_83","doi-asserted-by":"crossref","unstructured":"Weinberger, B., Haks, M.C., de Paus, R.A., Ottenhoff, T.H.M., Bauer, T., and Grubeck-Loebenstein, B. (2018). Impaired Immune Response to Primary but Not to Booster Vaccination Against Hepatitis B in Older Adults. Front. Immunol., 9.","DOI":"10.3389\/fimmu.2018.01035"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.vaccine.2017.11.037","article-title":"The efficacy of two different dosages of hepatitis B immunoglobulin combined with hepatitis B vaccine in preventing mother-to-child transmission of hepatitis B virus: A prospective cohort study","volume":"36","author":"Wei","year":"2018","journal-title":"Vaccine"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1080\/21645515.2018.1438090","article-title":"Comparison of immunogenicity between hepatitis B vaccines with different dosages and schedules among healthy young adults in China: A 2-year follow-up study","volume":"14","author":"Wang","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s13312-018-1227-2","article-title":"Long-term Protection Against the Hepatitis B Virus Detected Through an Early Response to a Booster Dose Injection","volume":"55","author":"Saffar","year":"2018","journal-title":"Indian Pediatr."},{"key":"ref_87","first-page":"E92","article-title":"Efficacy of Hepatitis B Vaccination among Children in Special Region of Yogyakarta, Indonesia: Evaluation of Humoral and Cellular Immunity","volume":"63","author":"Pronocitro","year":"2018","journal-title":"Kobe J. Med. Sci."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1773","DOI":"10.1080\/21645515.2018.1452578","article-title":"Immunogenicity, safety, and tolerability of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young Japanese adults","volume":"14","author":"Kishino","year":"2018","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/j.vaccine.2017.12.038","article-title":"Immunogenicity of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant compared with a licensed hepatitis B vaccine in adults","volume":"36","author":"Jackson","year":"2018","journal-title":"Vaccine"},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2604","DOI":"10.1016\/j.vaccine.2018.03.067","article-title":"Safety of a two-dose investigational hepatitis B vaccine, HBsAg-1018, using a toll-like receptor 9 agonist adjuvant in adults","volume":"36","author":"Hyer","year":"2018","journal-title":"Vaccine"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1097\/INF.0000000000001361","article-title":"Comparative Efficacy, Safety and Immunogenicity of Hepavax-Gene TF and Engerix-B Recombinant Hepatitis B Vaccines in Neonates in China","volume":"36","author":"Zhu","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1080\/23744235.2017.1292541","article-title":"No response to hepatitis B vaccine in infants born to HBsAg(+) mothers is associated to the transplacental transfer of HBsAg","volume":"49","author":"Wang","year":"2017","journal-title":"Infect. Dis."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"303","DOI":"10.26444\/aaem\/74716","article-title":"Predictors of Hepatitis B Surface Antigen Titers two decades after vaccination in a cohort of students and post-graduates of the Medical School at the University of Palermo, Italy","volume":"24","author":"Verso","year":"2017","journal-title":"Ann. Agric. Environ. Med. AAEM"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e208","DOI":"10.1097\/INF.0000000000001578","article-title":"Serologic Responses After Hepatitis B Vaccination in Preterm Infants Born to Hepatitis B Surface Antigen-Positive Mothers: Singapore Experience","volume":"36","author":"Tan","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1093\/infdis\/jix339","article-title":"The Impact of Hepatitis B Vaccine Failure on Long-term Natural Course of Chronic Hepatitis B Virus Infection in Hepatitis B e Antigen-Seropositive Children","volume":"216","author":"Tai","year":"2017","journal-title":"J. Infect. Dis."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1097\/INF.0000000000001543","article-title":"Will Infant Hepatitis B Vaccination Protect Into Adulthood?: Extended Canadian Experience After a 2-, 4- and 6-month Immunization Schedule","volume":"36","author":"Pinto","year":"2017","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.vaccine.2016.11.061","article-title":"Hepatitis B vaccine alone may be enough for preventing hepatitis B virus transmission in neonates of HBsAg (+)\/HBeAg (\u2212) mothers","volume":"35","author":"Lu","year":"2017","journal-title":"Vaccine"},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1080\/21645515.2016.1260794","article-title":"Effects of hepatitis B vaccine boosters on anti-HBs-negative children after primary immunization","volume":"13","author":"Lu","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_99","doi-asserted-by":"crossref","unstructured":"Lee, K.H., Shim, K.S., Lim, I.S., Chae, S.A., Yun, S.W., Lee, N.M., Choi, Y.B., and Yi, D.Y. (2017). Changes in hepatitis B virus antibody titers over time among children: A single center study from 2012 to 2015 in an urban of South Korea. BMC Pediatr., 17.","DOI":"10.1186\/s12887-017-0924-7"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"4515","DOI":"10.1016\/j.vaccine.2017.07.040","article-title":"Serological and molecular epidemiological outcomes after two decades of universal infant hepatitis B virus (HBV) vaccination in Nunavut, Canada","volume":"35","author":"Huynh","year":"2017","journal-title":"Vaccine"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.1080\/21645515.2016.1206676","article-title":"Rapid immunization effects of a new type of 60 \u03bcg hepatitis B vaccine compared with traditional 20 \u03bcg hepatitis B vaccines in adults","volume":"12","author":"Wang","year":"2016","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"2745","DOI":"10.1016\/j.vaccine.2016.04.013","article-title":"Immunity to hepatitis B persists in adolescents 15-16 years of age vaccinated in infancy with three doses of hepatitis B vaccine","volume":"34","author":"Behre","year":"2016","journal-title":"Vaccine"},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Klushkina, V.V., Kyuregyan, K.K., Kozhanova, T.V., Popova, O.E., Dubrovina, P.G., Isaeva, O.V., Gordeychuk, I.V., and Mikhailov, M.I. (2016). Impact of universal hepatitis B vaccination on prevalence, infection-associated morbidity and mortality, and circulation of immune escape variants in Russia. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0157161"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1111\/jvh.12543","article-title":"Immune responses to hepatitis B immunization 10\u201318 years after primary vaccination: A population-based cohort study","volume":"23","author":"Katoonizadeh","year":"2016","journal-title":"J. Viral Hepat."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/hep.27650","article-title":"Universal infant immunization and occult hepatitis B virus infection in children and adolescents: A population-based study","volume":"61","author":"Hsu","year":"2015","journal-title":"Hepatology"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Qu, C., Chen, T., Fan, C., Zhan, Q., Wang, Y., Lu, J., Lu, L.L., Ni, Z., Huang, F., and Yao, H. (2014). Efficacy of Neonatal HBV Vaccination on Liver Cancer and Other Liver Diseases over 30-Year Follow-up of the Qidong Hepatitis B Intervention Study: A Cluster Randomized Controlled Trial. PLoS Med., 11.","DOI":"10.1371\/journal.pmed.1001774"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"3706","DOI":"10.1016\/j.vaccine.2014.02.094","article-title":"Immune response to hepatitis B vaccine with high antigen content in non-responders after standard primary vaccination in Chinese adults","volume":"32","author":"Pan","year":"2014","journal-title":"Vaccine"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"2168432","DOI":"10.1080\/21645515.2023.2168432","article-title":"Impaired long-term anti-HBs responses in choronic hepatitis C patients: Results from a five-year follow-up study with healthy control","volume":"19","author":"Yan","year":"2023","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"100891","DOI":"10.1016\/j.aohep.2022.100891","article-title":"Impaired anti-HBV vaccine response in non-cirrhotic chronic HCV is not overcome by double dose regimen: Randomized control trial","volume":"28","author":"Medeiros","year":"2023","journal-title":"Ann. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1111\/tmi.13588","article-title":"Effectiveness of hepatitis B vaccination in chronic HCV patients after successful generic direct acting antiviral therapy: Significance of isolated hepatitis B core antibodies","volume":"26","author":"Metwally","year":"2021","journal-title":"Trop. Med. Int. Health TMIH"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/jvh.12163","article-title":"HCV E1E2-MF59 vaccine in chronic hepatitis C patients treated with PEG-IFN\u03b12a and Ribavirin: A randomized controlled trial","volume":"21","author":"Colombatto","year":"2014","journal-title":"J. Viral Hepat."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.1038\/mt.2013.119","article-title":"Therapeutic DNA vaccination using in vivo electroporation followed by standard of care therapy in patients with genotype 1 chronic hepatitis C","volume":"21","author":"Weiland","year":"2013","journal-title":"Mol. Ther."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"154766","DOI":"10.1016\/j.cyto.2019.154766","article-title":"Circulating interferon-\u03bb3 and post-vaccination antibodies against the surface antigen of hepatitis B virus in hemodialysis patients exposed to hepatitis E virus","volume":"123","author":"Grzegorzewska","year":"2019","journal-title":"Cytokine"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1016\/j.cmi.2019.01.015","article-title":"Immunogenicity and safety of an accelerated hepatitis E vaccination schedule in healthy adults: A randomized, controlled, open-label, phase IV trial","volume":"25","author":"Chen","year":"2019","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"336.e1","DOI":"10.1016\/j.cmi.2016.10.029","article-title":"Persistence of antibodies acquired by natural hepatitis E virus infection and effects of vaccination","volume":"23","author":"Su","year":"2017","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"5073","DOI":"10.1016\/j.vaccine.2017.05.072","article-title":"A phase 1 randomized open-label clinical study to evaluate the safety and tolerability of a novel recombinant hepatitis E vaccine","volume":"35","author":"Cao","year":"2017","journal-title":"Vaccine"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1056\/NEJMoa1406011","article-title":"Long-term efficacy of a hepatitis E vaccine","volume":"372","author":"Zhang","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Horta, D., Forn\u00e9, M., Agust\u00ed, A., Raga, A., Mart\u00edn-Cardona, A., Hern\u00e1ndez-Soto, J.M., Ruiz-Ram\u00edrez, P., and Esteve-Comas, M. (2022). Efficacy of Hepatitis B Virus Vaccines HBVaxpro40\u00a9 and Fendrix\u00a9 in Patients with Chronic Liver Disease in Clinical Practice. Vaccines, 10.","DOI":"10.3390\/vaccines10081323"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1007\/s10620-020-06437-6","article-title":"Two-Dose Hepatitis B Vaccine (Heplisav-B) Results in Better Seroconversion Than Three-Dose Vaccine (Engerix-B) in Chronic Liver Disease","volume":"66","author":"Amjad","year":"2021","journal-title":"Dig. Dis. Sci."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.cgh.2018.08.047","article-title":"Efficacy of High-Dose, Rapid, Hepatitis A and B Vaccination Schedules in Patients with Cirrhosis","volume":"17","author":"Wigg","year":"2019","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/jvh.13164","article-title":"Long-term consequences of stopping HBIG and\/or nucleotide analogues in liver transplant recipients administered hepatitis B vaccination to prevent HBV reinfection","volume":"26","author":"Duan","year":"2019","journal-title":"J. Viral Hepat."},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1002\/lt.24814","article-title":"Active immunization for prevention of De novo hepatitis B virus infection after adult living donor liver transplantation with a hepatitis B core antigen-positive graft","volume":"23","author":"Wang","year":"2017","journal-title":"Liver Transplant."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.dld.2016.10.013","article-title":"Good response to the primary course and booster dose of hepatitis B vaccine in children with non-alcoholic fatty liver disease","volume":"49","author":"Seniuta","year":"2017","journal-title":"Dig. Liver Dis."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"764234","DOI":"10.1155\/2014\/764234","article-title":"Reestablishment of active immunity against HBV graft reinfection after liver transplantation for HBV-related end stage liver disease","volume":"2014","author":"Lu","year":"2014","journal-title":"J. Immunol. Res."},{"key":"ref_125","first-page":"e15447","article-title":"Granulocyte colony stimulating factor adjuvant role on the immunological response to Hepatitis B vaccine in patients with cirrhosis: A double blind randomized placebo controlled trial","volume":"14","author":"Talebzadeh","year":"2014","journal-title":"Hepat. Mon."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1007\/s00535-013-0763-8","article-title":"Which patients respond best to hepatitis B vaccination after a hepatitis B virus-related liver transplantation?","volume":"48","author":"Takaki","year":"2013","journal-title":"J. Gastroenterol."},{"key":"ref_127","first-page":"258","article-title":"Immunogenicity and safety of hepatitis A vaccine in children with chronic liver disease","volume":"37","author":"Ferreira","year":"2003","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1053\/jhep.2003.50227","article-title":"Active immunization against de novo hepatitis B virus infection in pediatric patients after liver transplantation","volume":"37","author":"Chang","year":"2003","journal-title":"Hepatology"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1002\/hep.1840380407","article-title":"Immunization with an adjuvant hepatitis B vaccine after liver transplantation for hepatitis B-related disease","volume":"38","author":"Bienzle","year":"2003","journal-title":"Hepatology"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"3289","DOI":"10.1016\/S0041-1345(02)03572-8","article-title":"Can patients awaiting liver transplantation elicit an immune response to the hepatitis A vaccine?","volume":"34","author":"Smallwood","year":"2002","journal-title":"Transplant. Proc."},{"key":"ref_131","first-page":"168","article-title":"Successful immune response to a recombinant hepatitis B vaccine in children after liver transplantation","volume":"32","author":"Duca","year":"2001","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1053\/jlts.2001.23069","article-title":"Double-dose accelerated hepatitis B vaccine in patients with end-stage liver disease","volume":"7","author":"Arslan","year":"2001","journal-title":"Liver Transplant."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/00007890-200107270-00019","article-title":"Safety and efficacy of hepatitis A vaccination in liver transplantation recipients","volume":"72","author":"Arslan","year":"2001","journal-title":"Transplantation"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1053\/jhep.2001.25883","article-title":"Immunogenicity of hepatitis A vaccination in decompensated cirrhotic patients","volume":"34","author":"Arguedas","year":"2001","journal-title":"Hepatology"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1053\/jlts.2000.8313","article-title":"Vaccination against hepatitis B virus in cirrhotic patients on liver transplant waiting list","volume":"6","year":"2000","journal-title":"Liver Transplant."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"taae125","DOI":"10.1093\/jtm\/taae125","article-title":"Hepatitis a vaccine immunogenicity and boostability in adults receiving immunosuppressive therapy and adults living with HIV: A prospective single-centre cohort study","volume":"32","author":"Schnyder","year":"2025","journal-title":"J. Travel Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1001\/jama.2024.24490","article-title":"HepB-CpG vs HepB-Alum Vaccine in People with HIV and Prior Vaccine Nonresponse: The BEe-HIVe Randomized Clinical Trial","volume":"333","author":"Marks","year":"2025","journal-title":"JAMA"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.eimc.2023.03.003","article-title":"Low rate of vaccination and risk of incident hepatitis A among HIV-infected men who have sex with men in Seville, Southern Spain","volume":"42","author":"Macias","year":"2024","journal-title":"Enfermedades Infecc. Microbiol. Clin. (Engl. Ed.)"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2239946","DOI":"10.1080\/22221751.2023.2239946","article-title":"Durability of serologic responses to inactivated hepatitis A virus vaccination among people living with HIV following acute hepatitis A outbreak: A 5-year follow-up study","volume":"12","author":"Lin","year":"2023","journal-title":"Emerg. Microbes Infect."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"519","DOI":"10.7883\/yoken.JJID.2021.834","article-title":"Intradermal Hepatitis B Vaccination in Non-responder People Living with Human Immunodeficiency Virus in Japan","volume":"75","author":"Yoshimura","year":"2022","journal-title":"Jpn. J. Infect. Dis."},{"key":"ref_141","doi-asserted-by":"crossref","unstructured":"Thitipatarakorn, S., Chinbunchorn, T., Peelay, J., Seekaew, P., Amatavete, S., Sangsai, M., Pankam, T., Avihingsanon, A., Avery, M., and Phanuphak, P. (2022). Prevalence and the associated factors of hepatitis B and hepatitis C viral infections among HIV-positive individuals in same-day antiretroviral therapy initiation program in Bangkok, Thailand. BMC Public Health, 22.","DOI":"10.1186\/s12889-021-12429-6"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1080\/14760584.2022.2056024","article-title":"Immunogenicity and safety of 4 intramuscular standard-dose and high-dose hepatitis B vaccine in people living with HIV: A randomized, parallel-controlled trial","volume":"21","author":"Feng","year":"2022","journal-title":"Expert Rev. Vaccines"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"e2120929","DOI":"10.1001\/jamanetworkopen.2021.20929","article-title":"Comparative Efficacy of a High-Dose vs Standard-Dose Hepatitis B Revaccination Schedule Among Patients with HIV: A Randomized Clinical Trial","volume":"4","author":"Vargas","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1007\/s13312-021-2159-9","article-title":"Three vs Four Dose Schedule of Double Strength Recombinant Hepatitis-B Vaccine in HIV-infected Children: A Randomized Controlled Trial","volume":"58","author":"Jain","year":"2021","journal-title":"Indian Pediatr."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"3582","DOI":"10.1016\/j.vaccine.2021.05.044","article-title":"Immunogenicity and persistence of high-dose recombinant hepatitis B vaccine in adults infected with human immunodeficiency virus in China: A randomized, double-blind, parallel controlled trial","volume":"39","author":"Feng","year":"2021","journal-title":"Vaccine"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s12981-019-0225-3","article-title":"Immunogenicity and safety of 4 vs. 3 standard doses of HBV vaccination in HIV-infected adults with isolated anti-HBc antibody","volume":"16","author":"Laksananun","year":"2019","journal-title":"AIDS Res. Ther."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s12981-019-0249-8","article-title":"Higher rate of long-term serologic response of four double doses vs. standard doses of hepatitis B vaccination in HIV-infected adults: 4-year follow-up of a randomised controlled trial","volume":"16","author":"Chaiwarith","year":"2019","journal-title":"AIDS Res. Ther."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1002\/jmv.25049","article-title":"Antibody response to hepatitis B vaccine in HIV-exposed infants in Malawi and correlation with HBV infection acquisition","volume":"90","author":"Mancinelli","year":"2018","journal-title":"J. Med. Virol."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1002\/hep.29780","article-title":"Serologic responses and effectiveness of hepatitis A vaccination among human immunodeficiency virus-positive individuals during the outbreak of acute hepatitis A","volume":"68","author":"Lin","year":"2018","journal-title":"Hepatology"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1016\/j.vaccine.2018.02.018","article-title":"Evaluation of a convenient vaccination schedule against hepatitis B in HIV-patients with undetectable HIV viral load","volume":"36","author":"Kourkounti","year":"2018","journal-title":"Vaccine"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/liv.13665","article-title":"Serological responses to revaccination with hepatitis A virus (HAV) vaccines among HIV-positive individuals whose anti-HAV antibody waned after primary vaccination","volume":"38","author":"Chen","year":"2018","journal-title":"Liver Int."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"8350862","DOI":"10.1155\/2018\/8350862","article-title":"Hepatitis B Vaccination Induced TNF-\u03b1- and IL-2-Producing T Cell Responses in HIV- Healthy Individuals Higher than in HIV+ Individuals Who Received the Same Vaccination Regimen","volume":"2018","author":"Chawansuntati","year":"2018","journal-title":"J. Immunol. Res."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1007\/s13312-017-1203-2","article-title":"Double Dose Versus Standard Dose Hepatitis B Vaccine in HIV-infected Children: A Randomized Controlled Trial","volume":"54","author":"Siddiqui","year":"2017","journal-title":"Indian Pediatr."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"8956","DOI":"10.1038\/s41598-017-09165-6","article-title":"T follicular helper cells and antibody response to Hepatitis B virus vaccine in HIV-1 infected children receiving ART","volume":"7","author":"Bekele","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1093\/infdis\/jiw011","article-title":"Vaccination Against Hepatitis B Virus (HBV) in HIV-1-Infected Patients with Isolated Anti-HBV Core Antibody: The ANRS HB EP03 CISOVAC Prospective Study","volume":"213","author":"Piroth","year":"2016","journal-title":"J. Infect. Dis."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1016\/j.vaccine.2016.02.055","article-title":"CD4\/CD8 ratio as a predictor of the response to HBV vaccination in HIV-positive patients: A prospective cohort study","volume":"34","author":"Fuster","year":"2016","journal-title":"Vaccine"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1007\/s12098-015-1984-z","article-title":"Immune Response to Double Dose Hepatitis-B Vaccine using Four Dose Schedule in HIV Infected Children","volume":"83","author":"Bose","year":"2016","journal-title":"Indian J. Pediatr."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1016\/S1473-3099(15)00220-0","article-title":"Safety and immunogenicity of double-dose versus standard-dose hepatitis B revaccination in non-responding adults with HIV-1 (ANRS HB04 B-BOOST): A multicentre, open-label, randomised controlled trial","volume":"15","author":"Rey","year":"2015","journal-title":"Lancet Infect. Dis."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1097\/INF.0b013e318271b93d","article-title":"Hepatitis B virus prevalence and vaccine response in HIV-infected children and adolescents on combination antiretroviral therapy in Kigali, Rwanda","volume":"32","author":"Mutwa","year":"2013","journal-title":"Pediatr. Infect. Dis. J."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1093\/infdis\/jis695","article-title":"Immune response to hepatitis B virus vaccination among HIV-1 infected and uninfected adults in Kenya","volume":"207","author":"Irungu","year":"2013","journal-title":"J. Infect. Dis."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"5973","DOI":"10.1016\/j.vaccine.2012.07.028","article-title":"Vaccination against hepatitis B with 4-double doses increases response rates and antibodies titers in HIV-infected adults","volume":"30","author":"Potsch","year":"2012","journal-title":"Vaccine"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1001\/jama.2011.351","article-title":"Safety and immunogenicity of 4 intramuscular double doses and 4 intradermal low doses vs standard hepatitis B vaccine regimen in adults with HIV-1: A randomized controlled trial","volume":"305","author":"Launay","year":"2011","journal-title":"JAMA"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1093\/aje\/kwq326","article-title":"The timing of hepatitis B virus (HBV) immunization relative to human immunodeficiency virus (HIV) diagnosis and the risk of HBV infection following HIV diagnosis","volume":"173","author":"Landrum","year":"2011","journal-title":"Am. J. Epidemiol."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1097\/QAI.0b013e318203e9f2","article-title":"Hepatitis B vaccination in HIV-infected youth: A randomized trial of three regimens","volume":"56","author":"Flynn","year":"2011","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1093\/infdis\/jiq137","article-title":"A randomized controlled study of accelerated versus standard hepatitis B vaccination in HIV-positive patients","volume":"203","author":"Hansen","year":"2011","journal-title":"J. Infect. Dis."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"3672","DOI":"10.1016\/j.vaccine.2010.03.022","article-title":"Impaired generation of hepatitis B virus-specific memory B cells in HIV infected individuals following vaccination","volume":"28","author":"Mehta","year":"2010","journal-title":"Vaccine"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1086\/605448","article-title":"Immunogenicity and immunologic memory after hepatitis B virus booster vaccination in HIV-infected children receiving highly active antiretroviral therapy","volume":"200","author":"Abzug","year":"2009","journal-title":"J. Infect. Dis."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/QAI.0b013e318183a9c0","article-title":"Immunological efficacy of a three-dose schedule of hepatitis A vaccine in HIV-infected adults: HEPAVAC study","volume":"49","author":"Launay","year":"2008","journal-title":"J. Acquir. Immune Defic. Syndr."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1086\/524690","article-title":"A prospective open study of the efficacy of high-dose recombinant hepatitis B rechallenge vaccination in HIV-infected patients","volume":"197","author":"Hansen","year":"2008","journal-title":"J. Infect. Dis."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"6310","DOI":"10.1016\/j.vaccine.2007.06.013","article-title":"Immunogenicity and safety of a virosomal hepatitis A vaccine in HIV-positive patients","volume":"25","author":"Loutan","year":"2007","journal-title":"Vaccine"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1742-6405-3-9","article-title":"Randomized controlled trial of hepatitis B virus vaccine in HIV-1-infected patients comparing two different doses","volume":"3","year":"2006","journal-title":"AIDS Res. Ther."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1086\/429302","article-title":"Response to hepatitis B vaccine in HIV-1-positive subjects who test positive for isolated antibody to hepatitis B core antigen: Implications for hepatitis B vaccine strategies","volume":"191","author":"Gandhi","year":"2005","journal-title":"J. Infect. Dis."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.vaccine.2004.05.010","article-title":"Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects","volume":"23","author":"Ristola","year":"2004","journal-title":"Vaccine"},{"key":"ref_174","first-page":"269","article-title":"The response to hepatitis B virus vaccine in HIV-infected patients","volume":"6","author":"Alaei","year":"2003","journal-title":"Arch. Iran. Med."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S1054-139X(01)00278-6","article-title":"Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort","volume":"29","author":"Wilson","year":"2001","journal-title":"J. Adolesc. Health"},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/S0264-410X(99)00389-8","article-title":"Increasing the number of hepatitis B vaccine injections augments anti-HBs response rate in HIV-infected patients. Effects on HIV-1 viral load","volume":"18","author":"Rey","year":"2000","journal-title":"Vaccine"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"101479","DOI":"10.1016\/j.tmaid.2019.101479","article-title":"Hepatitis A vaccine immunogenicity in patients using immunosuppressive drugs: A systematic review and meta-analysis","volume":"32","author":"Veurink","year":"2019","journal-title":"Travel Med. Infect. Dis."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1080\/21645515.2016.1242539","article-title":"Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines\u2013A systematic review","volume":"13","author":"Stuurman","year":"2017","journal-title":"Hum. Vaccines Immunother."},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"1","DOI":"10.12932\/AP-220125-2021","article-title":"Lessons from Thailand\u2019s successful prevention of mother-to-child hepatitis B transmission: Advancing toward elimination by 2030","volume":"43","author":"Poovorawan","year":"2025","journal-title":"Asian Pac. J. Allergy Immunol."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Flores, J.E., Thompson, A.J., Ryan, M., and Howell, J. (2022). The Global Impact of Hepatitis B Vaccination on Hepatocellular Carcinoma. Vaccines, 10.","DOI":"10.3390\/vaccines10050793"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1080\/14760584.2023.2274482","article-title":"PreHevbrio: The first approved 3-antigen hepatitis B vaccine","volume":"22","author":"Vesikari","year":"2023","journal-title":"Expert Rev. Vaccines"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"2376","DOI":"10.1001\/jama.2023.23242","article-title":"Hepatitis D: A Review","volume":"330","author":"Negro","year":"2023","journal-title":"JAMA"},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1002\/hep.27742","article-title":"Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program","volume":"61","author":"Lin","year":"2015","journal-title":"Hepatology"},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1590\/S0037-86822012000600007","article-title":"Hepatitis D virus infection in the western brazilian amazon\u2014Far from a vanishing disease","volume":"45","author":"Braga","year":"2012","journal-title":"Rev. Soc. Bras. Med. Trop."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1111\/1469-0691.12493","article-title":"Why is it so difficult to develop a hepatitis C virus preventive vaccine?","volume":"20","author":"Zingaretti","year":"2014","journal-title":"Clin. Microbiol. Infect."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2254","DOI":"10.1080\/21645515.2018.1469591","article-title":"Development of new hepatitis E vaccines","volume":"14","author":"Cao","year":"2018","journal-title":"Hum. Vaccines Immunother."}],"container-title":["Vaccines"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/49\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:23:46Z","timestamp":1767198226000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2076-393X\/14\/1\/49"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":186,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["vaccines14010049"],"URL":"https:\/\/doi.org\/10.3390\/vaccines14010049","relation":{},"ISSN":["2076-393X"],"issn-type":[{"value":"2076-393X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}